XML 73 R62.htm IDEA: XBRL DOCUMENT v3.20.2
Segment Information (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2020
USD ($)
segment
Jun. 30, 2019
USD ($)
Segment Reporting Information [Line Items]        
Number of reportable segments | segment     2  
Revenue, net $ 2,046 $ 886 $ 3,453 $ 2,149
Cost of revenue 1,389 994 2,658 2,201
Research and development 6,466 17,519 15,909 37,161
General and administrative 5,572 7,469 11,773 14,926
Goodwill impairment   18,504   18,504
Loss from operations (11,381) (43,600) (26,887) (70,643)
Loss from discontinued operations (27) (6,191) (285) (16,483)
Dermatology Therapeutics Segment        
Segment Reporting Information [Line Items]        
Revenue, net 193   411  
Research and development 6,577 17,615 16,121 37,352
General and administrative   359   477
Goodwill impairment   18,504   18,504
Loss from operations (6,384) (36,478) (15,710) (56,333)
Loss from discontinued operations (27) (5,298) (284) (14,720)
Contract Research Segment        
Segment Reporting Information [Line Items]        
Revenue, net 3,657 3,807 7,064 8,995
Cost of revenue 3,082 3,819 6,468 8,856
General and administrative 688 613 1,440 1,145
Loss from operations (113) (625) (844) (1,006)
Corporate and Other        
Segment Reporting Information [Line Items]        
Revenue, net (1,804) (2,921) (4,022) (6,846)
Cost of revenue (1,693) (2,825) (3,810) (6,655)
Research and development (111) (96) (212) (191)
General and administrative 4,884 6,497 10,333 13,304
Loss from operations $ (4,884) (6,497) (10,333) (13,304)
Loss from discontinued operations   $ (893) (1) (1,763)
Intersegment Eliminations | Contract Research Segment        
Segment Reporting Information [Line Items]        
Revenue, net     $ (4,022) $ (6,846)